Premium
Effects of Creatine Supplementation and Doxorubicin Treatment on Diaphragm Myogenic Regulatory Factor Expression
Author(s) -
Jones Megan,
Busekrus Raquel,
Torok Zoltan,
Hydock David
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.769.3
Subject(s) - myf5 , myod , diaphragm (acoustics) , myogenic regulatory factors , doxorubicin , creatine , endocrinology , medicine , andrology , chemotherapy , chemistry , biology , pharmacology , myocyte , myogenesis , physics , acoustics , loudspeaker
The purpose of this study was to explore the effects of creatine monohydrate (Cr) supplementation and the chemotherapy drug doxorubicin (DOX) on myogenic regulatory factor (MRF) expression in the diaphragm. Male Sprague‐Dawley rats were fed either a diet supplemented with 3% Cr or a standard control (CON) diet for two weeks. Animals were then randomly assigned to receive 15 mg/kg of DOX or saline (SAL) as a placebo. After five days, animals were anesthetized, diaphragms were removed, and expression of the primary MRFs MyoD and Myf5 were quantified using Western blotting. When compared to CON+SAL diaphragm, MyoD expression was 24% and 31% lower in diaphragms from CON+DOX and Cr+DOX, respectively. Myf5 expression was 15% and 41% higher in diaphragm from CON+DOX and Cr+DOX, respectively, when compared to CON+SAL diaphragm. A trend toward DOX decreasing MyoD and increasing Myf5 expression in diaphragm was observed, and the trend toward Cr increasing Myf5 expression with DOX treatment warrants further investigation. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .